HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.

AbstractBACKGROUND:
A diagnosis of chronic lymphocytic leukemia (CLL) requires a count of over 5000 circulating CLL-phenotype cells per cubic millimeter. Asymptomatic persons with fewer CLL-phenotype cells have monoclonal B-cell lymphocytosis (MBL). The goal of this study was to investigate the relation between MBL and CLL.
METHODS:
We investigated 1520 subjects who were 62 to 80 years of age with a normal blood count and 2228 subjects with lymphocytosis (>4000 lymphocytes per cubic millimeter) for the presence of MBL, using flow cytometry. Monoclonal B cells were further characterized by means of cytogenetic and molecular analyses. A representative cohort of 185 subjects with CLL-phenotype MBL and lymphocytosis were monitored for a median of 6.7 years (range, 0.2 to 11.8).
RESULTS:
Monoclonal CLL-phenotype B cells were detected in 5.1% of subjects (78 of 1520) with a normal blood count and 13.9% (309 of 2228) with lymphocytosis. CLL-phenotype MBL had a frequency of 13q14 deletion and trisomy 12 similar to that of CLL and showed a skewed repertoire of the immunoglobulin heavy variable group (IGHV) genes. Among 185 subjects presenting with lymphocytosis, progressive lymphocytosis occurred in 51 (28%), progressive CLL developed in 28 (15%), and chemotherapy was required in 13 (7%). The absolute B-cell count was the only independent prognostic factor associated with progressive lymphocytosis. During follow-up over a median of 6.7 years, 34% of subjects (62 of 185) died, but only 4 of these deaths were due to CLL. Age above 68 years and hemoglobin level below 12.5 g per deciliter were the only independent prognostic factors for death.
CONCLUSIONS:
The CLL-phenotype cells found in the general population and in subjects with lymphocytosis have features in common with CLL cells. CLL requiring treatment develops in subjects with CLL-phenotype MBL and with lymphocytosis at the rate of 1.1% per year.
AuthorsAndy C Rawstron, Fiona L Bennett, Sheila J M O'Connor, Marwan Kwok, James A L Fenton, Marieth Plummer, Ruth de Tute, Roger G Owen, Stephen J Richards, Andrew S Jack, Peter Hillmen
JournalThe New England journal of medicine (N Engl J Med) Vol. 359 Issue 6 Pg. 575-83 (Aug 07 2008) ISSN: 1533-4406 [Electronic] United States
PMID18687638 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright2008 Massachusetts Medical Society
Chemical References
  • Genetic Markers
  • Hemoglobins
  • Immunoglobulin Heavy Chains
Topics
  • Age Factors
  • Aged
  • Aged, 80 and over
  • B-Lymphocytes (immunology)
  • Cohort Studies
  • DNA Mutational Analysis
  • Disease Progression
  • Female
  • Genes, Immunoglobulin
  • Genetic Markers
  • Germ-Line Mutation
  • Hemoglobins (analysis)
  • Humans
  • Immunoglobulin Heavy Chains (genetics)
  • Kaplan-Meier Estimate
  • Leukemia, Lymphocytic, Chronic, B-Cell (immunology, mortality)
  • Lymphocyte Count
  • Lymphocytosis (immunology)
  • Male
  • Middle Aged
  • Phenotype
  • Precancerous Conditions (immunology)
  • Prognosis
  • Reference Values

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: